Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Daiichi Sankyo Ltd
(OP:
DSKYF
)
39.20
+1.80 (+4.81%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Daiichi Sankyo Ltd
< Previous
1
2
Next >
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
August 10, 2024
Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones.
Via
Talk Markets
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
August 07, 2024
"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say.
Via
Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
July 30, 2024
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...
Via
Benzinga
Exposures
Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
June 27, 2024
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The...
Via
Benzinga
Exposures
Product Safety
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
June 24, 2024
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via
Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
Via
Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
January 13, 2023
Via
Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Via
Benzinga
Double Good News For AstraZeneca's Breast Cancer Drugs
April 29, 2024
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Via
Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...
Via
Benzinga
Exposures
Product Safety
What's Going On With Pfizer Stock Today?
January 25, 2024
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.
Via
Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
Via
Benzinga
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:
Via
Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria
Via
Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in
Via
Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
Via
Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
Via
Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
Via
Benzinga
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
August 15, 2022
Via
Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
Via
Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
Via
Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
July 19, 2022
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
June 27, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 6
June 06, 2022
Reuters
Via
Benzinga
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
June 06, 2022
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.